Results 61 to 70 of about 200,922 (348)

A Multi-Level Fit-Based Quality Improvement Initiative to Improve Colorectal Cancer Screening in a Managed Care Population. [PDF]

, 2018
IntroductionColorectal cancer (CRC) is a common but largely preventable disease with suboptimal screening rates despite national guidelines to screen individuals age 50-75.
Betlachin, Anna, Esrailian, Eric, Garner, Omai B, Grossman, Mark, Hommes, Daniel W, May, Folasade P, Skootsky, Samuel, Yu, Christine   +7 more
core  

Population screening for colorectal cancer means getting FIT:the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT) [PDF]

, 2014
Fecal immunochemical tests for hemoglobin (FIT) are changing the manner in which colorectal cancer (CRC) is screened. Although these tests are being performed worldwide, why is this test different from its predecessors?
Ahlquist, Allison, Allison, Allison, Allison, Atkin, Barrows, Brenner, Burtonwood, Callum G. Fraser, Center, Cole, Cole, Cole, Cole, Crotta, Denters, Digby, Fleisher, Fletcher, Fraser, Fraser, Fraser, Fraser, Fraser, Graeme P. Young, Grazzini, Halloran, Hardcastle, Hewitson, Hoff, Hol, Imperiale, Imperiale, James E. Allison, Jemal, Jemal, Khalid-de Bakker, Kronborg, Levi, Levi, Levin, Mandel, Morikawa, Niv, Osborn, Park, Petrelli, Potter, Potter, Potter, Potter, Potter, Qaseem, Quintero, Raginel, Robinson, Rozen, Saito, Saito, Schoen, Segnan, Segnan, Shaukat, Shimbo, Simon, Songster, Songster, St John, Steele, Steele, Stegeman, Stephen P. Halloran, Sugerman, Tao, van Roon, van Roon, van Roon, van Rossum, Vart, Vellacott, Ventura, Walsh, Williams, Young, Zajac, Zauber   +86 more
core   +2 more sources

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

County‐level colorectal cancer screening rates on colorectal cancer survival in the state of Georgia: Does county‐level rurality matter?

Cancer Medicine
Purpose Investigating CRC screening rates and rurality at the county‐level may explain disparities in CRC survival in Georgia. Although a few studies examined the relationship of CRC screening rates, rurality, and/or CRC outcomes, they either used an ...
Meng‐Han Tsai, Steven S. Coughlin, Jorge Cortes   +2 more
doaj   +1 more source

Evidence‐based consumer choice: a case study in colorectal cancer screening

Australian and New Zealand Journal of Public Health, 2003
Objectives:To elicit community preferences for colorectal cancer (CRC) screening by faecal occult blood test (FOBT) using discrete choice modeling (DCM).
Glenn Salkeld, Michael Solomon, Leonie Short, Mandy Ryan, Jeanette E. Ward   +4 more
doaj   +1 more source

“Sorry for laughing, but it’s scary”: humor and silence in discussions of Colorectal Cancer with Urban American Indians

BMC Cancer, 2023
Background Given high rates of cancer mortality in Native communities, we examined how urban American Indian and Alaska Native elders talk about colorectal cancer (CRC) and CRC screening.
Dedra S. Buchwald, Deborah R. Bassett, Emily R. Van Dyke, Raymond M. Harris, Jessica D. Hanson, Shin-Ping Tu   +5 more
doaj   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Risk of advanced colorectal neoplasia according to age and gender. [PDF]

, 2011
Colorectal cancer (CRC) is one of the leading causes of cancer related morbidity and death. Despite the fact that the mean age at diagnosis of CRC is lower in men, screening by colonoscopy or fecal occult blood test (FOBT) is initiated at same age in ...
Crispin, Alexander, Göke, Burkhard, Kolligs, Frank T., Mansmann, Ulrich, Munte, Axel, Wagner, Andreas   +5 more
core   +5 more sources

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Examining the relationship between household wealth and colorectal cancer screening behaviors among U.S. men aged 45–75

SSM: Population Health, 2022
Colorectal cancer (CRC) is the third leading cause of cancer-related death among men in the United States (U.S.), particularly among men aged 45 years and older.
Kevin M. Korous, Adolfo G. Cuevas, Jad Chahoud, Uchenna C. Ogbonnaya, Ellen Brooks, Charles R. Rogers   +5 more
doaj